Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBITDA (2016 - 2025)

Historic EBITDA for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $22.9 million.

  • Veracyte's EBITDA rose 9094.62% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 20516.99%. This contributed to the annual value of $16.1 million for FY2024, which is 11881.46% up from last year.
  • As of Q3 2025, Veracyte's EBITDA stood at $22.9 million, which was up 9094.62% from -$5.3 million recorded in Q2 2025.
  • Veracyte's EBITDA's 5-year high stood at $22.9 million during Q3 2025, with a 5-year trough of -$41.9 million in Q1 2021.
  • In the last 5 years, Veracyte's EBITDA had a median value of -$9.0 million in 2021 and averaged -$9.0 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 55511.07% in 2023, then soared by 16237.11% in 2025.
  • Veracyte's EBITDA (Quarter) stood at -$12.3 million in 2021, then soared by 56.05% to -$5.4 million in 2022, then crashed by 555.11% to -$35.5 million in 2023, then surged by 111.76% to $4.2 million in 2024, then skyrocketed by 449.6% to $22.9 million in 2025.
  • Its last three reported values are $22.9 million in Q3 2025, -$5.3 million for Q2 2025, and $2.9 million during Q1 2025.